Shebli Atrash

1 month ago | nature.com | James Davis |Mikhaila Rice |Kelley Julian |Charlotte Wagner |Shebli Atrash |Jack Khouri | +1 more

TO THE EDITOR:Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by the activation of T-cells and is commonly seen in patients receiving immune effector cell therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) which target varying tumor antigens such as CD19, CD20, B-cell maturation antigen (BCMA), or GPRC5D depending on the type of malignancy.

Jan 23, 2023 | mdedge.com | Shebli Atrash

Information from Industry-Sponsored Content Publish date: January 23, 2023 Developed under the direction and sponsorship of Janssen Biotech, Inc. 2022. Dr. Atrash is a Clinical Professor of Medicine and Hematological Medical Oncologist at the Atrium Health Levine Cancer Institute in Charlotte, North Carolina. He is a paid consultant for Janssen and must present information in accordance with US Food & Drug Administration (FDA) guidelines.